Diphenylantimony(lll) and diorganotin(IV) derivatives of dithiophosphorus ligands, i.e.
INTRODUCTION
In recent years, the potential antitumor activity of organometallics, i.e. compounds containing direct metal-carbon bonds, has received an increased attention, since more and more derivatives of either transition and Main Group metals were found to exhibit interesting inhibitory properties on animal tumor systems. Among Main Group metal compounds, organotin(IV) derivatives occupy a top position related to their antitumor effects, with some of them being even more active than cisplatin in in vitro tests. [2] [3] [4] [5] [6] [7] [8] [9] Interest in organoantimony(lll) compounds as potential antitumor agents arose in recent years when diphenylantimony(lll) derivatives of dithiophosphorus ligands were reported as the first organoantimony compounds to exhibit antitumor properties in vitro and in vivo against Ehrlich ascites tumor. [10] [11] [12] Comparative studies in this mouse tumor system, using diphenylantimony(lll) and diphenyltin(IV) compounds containing the same dithiophosphorus ligands, pointed out that organometallic di-iso-propylphosphorodithioates were more active than diphenylphosphino-?3 Vol. 1, No. 1, 1993 .4ntitumour Organometallics. III. In Vivo Activity of Diphenylantimony (III) and Diorganotin (IV) Dithiophosphorus Derivatives against P388 Leukemia dithioato analogues, and the organoantimony derivatives were more active than organotins.
Moreover, Ph2SbS2P(OPr-i)2 (5 mg/kg/day, i.p. on days 1, 3 and 5) produced an increase in lifespan of 83% and a cure rate of 30% in mice bearing this tumor. 10 Here we report the results obtained using the same compounds as above, on P388 leukemia in mice. Additionally, a dibutyltin(IV) derivative, L e. n-Bu2Sn(S2PPh2)2, was included in the screening, since a lot of previous reports concerning the antitumor activity of organotins 5, 8, 9 have suggested that the presence of the di-n-butyltin moiety improve the in vitro inhibitory effects against human tumor cell lines hours.
Compounds. The organometallic compounds used as antitumor agents were prepared and purified as described earlier: bis(diphenylphosphinodithioato)diphenyltin(IV), Ph2Sn(S2PPh2)2 (compound 1 KP 1215), 13 bis(di-iso-propylphosphorodithioato)diphenyltin(IV), Ph2Sn[S2P(OPr-i)2]2 (compound 2 KP 1216), 14 bis(diphenylphosphinodithioato)di-n-butyltin(IV), n-Bu2Sn(S2PPh2)2 (compound :3 KP 1217), 13 (di-iso-propylphosphorodithioato)-diphenylantimony(lll), Ph2SbS2P(OPr-i)2 (compound 4 KP 1218), 15 and (diphenylphosphinodithioato)diphenylantimony(lll), Ph2SbS2PPh2 (compound 5 KP 1219). 16 In vivo experiments. P388 leukemia cells were implanted intraperitoneally into DBA/2 mice for propagation 7 days before the experiment. The tumor cells were taken from these animals at the begining of the experiment immediatelly after cervical dislocation. Then we implanted 106 of these cells, suspended in 0.2 ml of physiological saline, intraperitoneally into female BDF1 mice, body weight 20-22 g, for testing. Then the mice were arbitrarily divided into groups of each time six animals, with one group serving as control. Therapy started 24 hours post transplantationem (= day 1) with a single dose of the respective organometallic compounds, applied intraperitoneally as suspension in physiological saline. As emulsifiers we used cremophorEL/propylenglycole. Therapy was repeated on days 2 and 3.
RESULTS AND DISCUSSION
The organometallic compounds used in this screening differ not only in the nature of the metal, organic groups bound to the metal atom, presence of aryl or alkoxy groups attached to ?4 phosphorus, but also by the molecular structure in solid state (Figure 1 ). Thus, all three diorganotin(IV) derivatives are monomeric compounds. However, for diphenyl-and di-n-butyltin(IV) diphenylphosphinodithioates 1 and 3 the infrared and M6ssbauer data suggest an angular orientation of the Sn-C bonds and anisobidentate coordination of the dithioligands,13 while for the di-iso-pmpylphosphomdithioato analogue 2, the C-Sn-C angle is 180 and the ligands are isobidentate as determined by X-ray diffmctometry. 4 For both diphenylantimony(lll) derivatives 4 and 5, the solid state structures were also investigated by the X-ray method. The phosphomdithioato 4 has a polymeric chain structure developed through weak Sb...S secondary bonds, the ligand acting effectivelly as a triconnective moiety. 15 The dithioligand has also a triconnective behavior in the phosphinodithioato analogue 5;, but leading The antitumor effects of the above organometallic compounds against P388 leukemia in mice are listed in Table 1 . All the diorganotin(IV) derivatives 1, 2 and 3, and the (diphenylphosphinodithioato)diphenylantimony(lll) 5, exhibited only marginal activity (TIC ca. 120%). Although ?5 Synthesis, Structure and BiologiCal lctivity of6-R3Si(Ge, Sn)-Substituted .-Fluorouracils the T/C value of 127% obtained for compound 3 was the best in the series of organotins, the presence of the di-n-butyltin(IV) moiety did not spectacularly improve the antitumor properties.
As in the previous experiments on Ehrlich ascites tumor, 10"12 the most active compound was (di-iso-propylphosphomdithioato)diphenylantimony(lll). It exhibited a T/C of 136% at a dose of 5 mg/kg, administered on days 1, 2 and 3, after tumor transplantation. However, when increasing the dose, the toxic effect of this compound seems to be stronger, since a decreased T/C value (i. e. 118%) was obtained. 
